Our Mission
Biotech investing requires synthesizing data from dozens of sources — SEC filings, clinical trials, company presentations, deal announcements. We built Satya Bio to do that synthesis automatically, so investors can focus on what matters: making better decisions.
What We Track
60+ public biotech companies with full pipeline coverage
200+ drug assets across all clinical stages
10+ therapeutic target landscapes
$30B+ in licensing and M&A deal value
Catalyst tracking with automated date updates
How We're Different
Built by biotech investors, for biotech investors
We understand the questions you're actually trying to answer
Updated daily, not quarterly
Real-time catalyst tracking and pipeline updates
Primary source data, not aggregated news
SEC filings, ClinicalTrials.gov, FDA databases, company IR pages
Request Access
Currently in private beta with select funds
We'll be in touch within 24 hours